AllSci News
Eisai and Henlius seal USD 388m license deal for PD-1 serplulimab in Japan
Eisai Co., Ltd, a Tokyo-based pharmaceutical company, and Shanghai Henlius Biotech, Inc. announced an exclusive licensing agreement for serplulimab, a novel anti-PD-1…
Everest takes Asia commercial rights to Micot Pharma hyperparathyroidism drug
Everest Medicines, a biopharmaceutical company headquartered in Shanghai, announced an exclusive licensing agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd (Micot), based…
Eikon Therapeutics holds upsized USD 381m IPO to advance live-cell imaging pipeline
Eikon Therapeutics, Inc. (Nasdaq: EIKN) priced its upsized initial public offering (IPO) of 21,177,600 shares at USD 18.00 per share. The offering,…
Third Arc Bio raises USD 52m in Series A for multi-function antibodies
Third Arc Bio, a clinical-stage biotechnology company developing novel multifunctional antibodies, has closed a startup funding round, raising USD 52 million through…
Cumberland’s ifetroban secures US FDA Fast Track status for DMD heart disease
Nashville-based Cumberland Pharmaceuticals Inc. announced today that the US FDA has granted Fast Track Designation for its oral ifetroban therapy targeting heart…
Evogene and Shanghai Lishan Biopharmaceuticals Seal USD Global Microbiome Cancer Therapeutic Licensing Deal
Evogene Ltd. and Shanghai Lishan Biopharmaceuticals Co. have [announced an exclusive worldwide licensing agreement](https://www.prnewswire.com/news-releases/evogene-and-shanghai-lishan-biopharmaceuticals-co-announce-exclusive-licensing-agreement-for-bmc128-a-microbiome-based-therapeutic-for-renal-and-lung-cancer-302678749.html) for BMC128, a first-in-class microbiome-based therapeutic targeting re
Hookipa selling off remaining arenavirus-based oncology assets to NeoTrail
Austria-based Hookipa Pharma announced an agreement to sell its remaining oncology-focused immunotherapy assets to US-based biotech NeoTrail Therapeutics, primarily focused on two…
Genmab antibody GEN3018 enters first-in-human Phase I targeting AML, HR-MDS
In a significant step forward for hematological cancer treatment, Genmab has initiated a first-in-human trial of GEN3018, an investigational antibody with target…
AstraZeneca met with CRL for subcutaneous Saphnelo formulation in lupus
AstraZeneca said the US FDA issued a Complete Response Letter (CRL) to the supplemental New Drug Application (sNDA) for Saphnelo (anifrolumab) subcutaneous…
Vertex takes license to WuXi Bio’s trispecific T-cell engager for B-cell autoimmune disease
WuXi Biologics and Vertex Pharmaceuticals have signed a strategic licensing agreement covering an innovative trispecific T-cell Engager (TCE) targeting B-cell mediated autoimmune…
Ultragenyx gene therapy shows long-term promise in rare neurological disorder
Ultragenyx Pharmaceutical announced positive clinical trials for UX111 (rebisufligene etisparvovec), an investigational AAV9 gene therapy targeting Sanfilippo syndrome Type A, or mucopolysaccharidosis…
MeiraGTx to use ZipBio’s AI platform for geographic atrophy therapies
US-based firms ZipBio and MeiraGTx (Nasdaq: MGTX) entered into a strategic licensing agreement under which MeiraGTx will obtain exclusive rights to ZipBio’s…
SK Bioscience takes global rights to Gates MRI’s RSV antibody
SK Boscience revealed an exclusive licensing agreement with the Gates Medical Research Institute (Gates MRI) granting SK rights to develop and commercialize…
Pfizer/Metsera GLP-1 RA shows sustained weight loss with monthly dosing in Phase IIb
Pfizer announced positive topline results from the Phase IIb VESPER-3 trial evaluating its investigational, ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 (also referred…
Menarini’s Insilico-sourced KIF18A inhibitor reaches first-in-human milestone
Insilico Medicine revealed that the novel small molecule MEN2501, developed through Insilico’s generative AI drug discovery platform, has been dosed in a…
The AllSci Brief
Systematic R&D and deal news. Daily.